Cell sub-journal interpretation! Scientists dig deep into antibody spectrum to find a cure for SARS-CoV-2!

November 23, 2020 // -- Recently, an article appeared in the international magazine Cell Host. In a review published on Microbe entitled "Mining Antibody Repertoire for Solutions to SARS-CoV-2," scientists from the University of Pennsylvania and others have revealed potential convergence characteristics of these antibodies in the context of larger multiclonal responses by sequencing antibody spectrums from patients with severe COVID-19, and the researchers note that as databases continue to update and improve, it may be possible for future scientists to use antibody sequencing techniques to monitor viral-specific B cells after infection or vaccination. In the
study, researcher Nielsen and colleagues analyzed the antibody spectrum of 13 PCR-diagnosed and admitted COVID-19 patients, an important advantage of which was that their patients were investigated at multiple points in time, and colleagues revealed how these antibody spectrums changed during the early stages of infection in patients; (RBD) special antibodies, while the researchers sequenced and analyzed the levels of their extra-body peritonal blood monocytes using the genomic DNA of the patient's body, thus providing general insights into the cloning map, such as diversity and cloning burst size, and from an RNA perspective, the researchers were able to provide antibody segmentation and high fidelity sequences for high-frequency mutation analysis of soy cells, including a database of more than 1.2 million clones from 38 samples for comparison. The researchers used a control database from 114 healthy adults in a previous study as a control group, and in addition, they performed a single-cell strategy on selected samples and obtained anti-weight and light-chain readings for antibody cloning and specific analysis.
Photo Source: Medicalgraphics.de Defining the immune properties of SARS-CoV-2 may be a challenge for scientists, with COVID-19 having considerable disease heterogeneity and different antibody responses in the patient's body;
Most studies have sampled the blood of the patient's body, which is filled with a large number of B-cell and T-cell clones, most of which are not related to SARS-CoV-2, while tissue-based B-cell cloning, unlike B-cell cloning in the body's circulation, may be more relevant to disease, in addition to these difficulties, with meso-SARS The most relevant antibodies to -CoV-2 are very uncommon in the blood, although the antibodies in the serum are very easy to detect, and finally, the problems produced in the body's immune response are often private, such as a person's body may produce an immune-resolution strategy against the virus, but not necessarily to produce an antibody that can read "textbooks".
When the relevant research began, the public database of antigen-specific SARS-CoV-2 antibody sequences was still quite limited, and as the researchers point out, this study represents only one starting point and a useful reference library for virus-related sequences, the relationship between which remains to be further studied by later scientists on the nature of the body's immune response to the virus.
To speed up the identification of the most relevant immune bank characteristics of SARS-CoV-2, researchers need to share data between researchers, and researcher Nielsen and his colleagues are exemplary in sharing data and comparing different data, and researchers are now working together to develop antigen-specific B-cell and T-cell-based databases.
As more data becomes available through public databases, different research results will be consolidated to provide a reference library for antigen-specific and disease-related cloning esoteric esoterics, and it is believed that through further research by later scientists, they will have a more comprehensive understanding of the body's immune response to SARS-CoV-2.
() References: Wenzhao Meng, Aaron M. Rosenfeld, Eline T. Luning Prak. Mining the Antibody Repertoire for Solutions to SARS-CoV-2, Cell Host and Microbe (2020) doi:10.1016/j.chom.2020.09.010